Yoland C. Antill, MD, of Cabrini Health, discusses phase II data on the effect of durvalumab, a PD-L1 inhibitor, as a single agent in the setting of recurrent or advanced endometrial cancer. Her research compares the response in mismatch repair–deficient and –proficient tumors (Abstract 5501).
Hani M. Babiker, MD, of the The University of Arizona, discusses an emerging treatment that inhibits the mitotic spindle and disrupts tumor cell growth. The method has been approve...
Åsmund A. Fretland, MD, of Oslo University Hospital, discusses clinical trial findings on survival outcomes after laparoscopic vs open resection for colorectal liver metastas...
Hirotsugu Kenmotsu, MD, of Shizuoka Cancer Center, discusses the phase III JIPANG trial findings, which showed that pemetrexed plus cisplatin was not superior to vinorelbine plus c...
Miriam Knoll, MD, and Zachery Reichert, MD, PhD, discuss the FORCE trial, which is examining whether radiation can create a more durable response to systemic...
Brian C. Baumann, MD, of Washington University School of Medicine, discusses study findings suggesting postoperative radiotherapy may be an option for patients with locally advance...